NCT05369221 is a Phase 1 clinical trial of ReSpace™ in Uterine Cervical Neoplasms, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05369221?

NCT05369221 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05369221?

Interventions in NCT05369221: ReSpace™.

What condition does NCT05369221 study?

NCT05369221 studies Uterine Cervical Neoplasms.

Is NCT05369221 still recruiting?

NCT05369221 is currently completed. Last updated 13 November 2023.

Last reviewed 2023-11-13 · How we verify

NCT05369221

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space

Completed Phase 1 Last updated 13 November 2023

What this trial tests

Phase 1 trial testing ReSpace™ in Uterine Cervical Neoplasms in 8 participants. Completed in 10 October 2023.

Timeline

25 April 2022

Primary endpoint
10 October 2023

10 October 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	25 April 2022
Primary completion	10 October 2023
Estimated completion	10 October 2023
Sites	1 location across China

Drugs / interventions tested

ReSpace™

Conditions studied

Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, female only, with Uterine Cervical Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, 5 subjects will be enrolled and the cumulative D2cc dose for rectum during brachytherapy will be recorded as the primary outcome measures.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A phase I clinical trial evaluating the application of hydrogel in reducing rectal dose during cervical cancer brachytherapy.
Wang Y, Zhen H, Hu K, Yu L, et al · · 2024 · cited 5× · PMID 39386060 · DOI 10.1016/j.ctro.2024.100867
Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems.
Carballo-Pedrares N, Giménez VMM, Alonso MJ. · · 2026 · cited 2× · PMID 41571911 · DOI 10.1007/s13346-025-02033-1

Verify or expand the search:

Other recruiting trials for Uterine Cervical Neoplasms

Currently open trials in the same condition.

NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting
NCT07011836 — Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women · NA · recruiting
NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
NCT06558682 — Neoadjuvant Therapy in Cervical Cancer · NA · recruiting
NCT06509724 — Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy · Phase 3 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05369221 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 13 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05369221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing